# Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

> **NCT07307235** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 1316 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** iGlarLixi (insulin glargine/lixisenatide)
- **DRUG:** standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)

## Key facts

- **NCT ID:** NCT07307235
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 1316 (ESTIMATED)
- **Last updated:** 2025-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07307235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07307235, "Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07307235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*